AU2023205553A1 - Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions - Google Patents

Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions Download PDF

Info

Publication number
AU2023205553A1
AU2023205553A1 AU2023205553A AU2023205553A AU2023205553A1 AU 2023205553 A1 AU2023205553 A1 AU 2023205553A1 AU 2023205553 A AU2023205553 A AU 2023205553A AU 2023205553 A AU2023205553 A AU 2023205553A AU 2023205553 A1 AU2023205553 A1 AU 2023205553A1
Authority
AU
Australia
Prior art keywords
compound
certain embodiments
deuterium
nsd2
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023205553A
Other languages
English (en)
Inventor
Terrence Joseph Connolly
Chad Arthur LEWIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K36 Therapeutics Inc
Original Assignee
K36 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc filed Critical K36 Therapeutics Inc
Publication of AU2023205553A1 publication Critical patent/AU2023205553A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023205553A 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions Pending AU2023205553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
US63/296,676 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (1)

Publication Number Publication Date
AU2023205553A1 true AU2023205553A1 (en) 2024-07-25

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023205553A Pending AU2023205553A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Country Status (10)

Country Link
US (2) US12492203B2 (https=)
EP (1) EP4460502A4 (https=)
JP (1) JP2025504379A (https=)
KR (1) KR20240158230A (https=)
CN (1) CN119032094A (https=)
AU (1) AU2023205553A1 (https=)
CA (1) CA3242612A1 (https=)
IL (1) IL314062A (https=)
MX (1) MX2024008450A (https=)
WO (1) WO2023133201A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
AU2023397773A1 (en) * 2022-12-12 2025-06-26 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) * 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
US20220380371A1 (en) 2019-09-20 2022-12-01 Novartis Ag Mll1 inhibitors and anti-cancer agents
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2023225154A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
AU2023273656A1 (en) 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
US20250206740A1 (en) 2022-05-23 2025-06-26 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
EP4583915A1 (en) 2022-09-09 2025-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
AU2023397773A1 (en) 2022-12-12 2025-06-26 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
EP4460502A1 (en) 2024-11-13
IL314062A (en) 2024-09-01
MX2024008450A (es) 2024-12-06
CA3242612A1 (en) 2023-07-13
US20260049083A1 (en) 2026-02-19
US20240352017A1 (en) 2024-10-24
US12492203B2 (en) 2025-12-09
EP4460502A4 (en) 2025-12-24
CN119032094A (zh) 2024-11-26
JP2025504379A (ja) 2025-02-12
WO2023133201A1 (en) 2023-07-13
KR20240158230A (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
US12492203B2 (en) Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
US20250326752A1 (en) Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20240002385A1 (en) Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250171445A1 (en) Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
AU2023397773A1 (en) Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
WO2023230026A1 (en) Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2023230038A1 (en) Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
EP4013756B1 (en) Mll1 inhibitors and anti-cancer agents
EP4013754B1 (en) Mll1 inhibitors and anti-cancer agents
US20240415864A1 (en) Carbohydrate-functionalized piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions
WO2025259850A1 (en) Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20240417401A1 (en) Heterobicyclic-methylpurine pyridines and related compounds and their use in treating diseases and conditions
US20250163067A1 (en) Nucleobase-substituted piperidinyl-pyridines and related compounds and their use in treating diseases and conditions
WO2024258897A1 (en) Alkoxypyridinyl and related compounds and their use in therapy
WO2025117672A1 (en) Indazolyl-piperidine sulfonamides and related compounds and their use in therapy
WO2024229401A2 (en) Diazepino-thieno-quinoxaline compounds and their use in therapy
WO2026055333A1 (en) Methods for treating and selecting cancer patients
WO2025194014A1 (en) Hetero aryl modulators of apmap and uses thereof